A New Mutational and Epigenetic Signature to Predict Early OPSCC Relapse
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Elisabetta Fratta, PhD
- Phone Number: +390434659569
- Email: efratta@cro.it
Study Contact Backup
- Name: Giuseppe Fanetti, MD
- Phone Number: +390434659525
- Email: giuseppe.fanetti@cro.it
Study Locations
-
-
-
Aviano, Italy
- Recruiting
- Centro di Riferimento Oncologico (CRO), IRCCS
-
Contact:
- Elisabetta Fratta, MD
- Email: efratta@cro.it
-
Principal Investigator:
- Elisabetta Fratta, PhD
-
Belluno, Italy
- Recruiting
- Ospedale San Martino di Belluno - ULSS 1 Dolomiti
-
Contact:
- Carlo Furlan, MD
- Email: carlo.furlan@aulss1.veneto.it
-
Mestre, Italy
- Recruiting
- Ospedale dell'Angelo - Mestre - Ulss 3 Serenissima
-
Contact:
- Doriano Politi, MD
- Email: doriano.politi@aulss3.veneto.it
-
Pordenone, Italy
- Recruiting
- Ospedale Santa Maria degli Angeli - ASFO
-
Contact:
- Vittorio Giacomarra
- Email: vittorio.giacomarra@asfo.sanita.fvg.it
-
Treviso, Italy
- Recruiting
- Ospedale di Treviso - ULSS 2 Marca Trevigiana
-
Contact:
- Paolo Boscolo-Rizzo, MD
- Email: segorltv@aulss2.veneto.it
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- newly diagnosed, previously untreated, histologically confirmed stage III-IVa OPSCC, according to AJCC 7th Edition,
- managed with definitive treatment modality (either radical surgery plus adjuvant radiotherapy ± chemotherapy or definitive chemo-radiotherapy)
- minimum follow up of 2 years or who had disease recurrence within 2 years after the end of treatment.
- neoplastic lesion contains ≥ 70% neoplastic cells
Exclusion Criteria:
Patients:
- with distant metastases at diagnosis,
- who have been managed with palliative intent;
- with previous history of head and neck cancer are not eligible
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
risk of recurrence
Time Frame: 18 months
|
risk of recurrence in patients with a negative prognostic epigenetic signature compared to patients with a positive one
|
18 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Elisabetta Fratta, PhD, Centro di Riferimento Oncologico (CRO), IRCCS
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CRO 2019.13
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.